KURA vs ATTO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
KURA · Kura Oncology$6.91 ▼ 5.99%
ATTO · Attovia Therapeutics$15.10 ▼ 3.08%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- KURA -24.9%
- ATTO -31.1%
Head to head
| Metric | KURA | ATTO |
|---|---|---|
| Price | $6.91 | $15.10 |
| Change today | ▼ 5.99% | ▼ 3.08% |
| Market cap | $634.88M | $690.26M |
| Return, 3 months | -44.3% | -26.8% |
| Return, year to date | -33.5% | – |
| Return, 1 year | -38.1% | – |
| P/E (TTM) | – | – |
| P/B | 35.4 | 1.7 |
| P/E percentile vs own 5y | 99th | 94th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +10.1% | -100.0% |
| Net profit growth (YoY) | +5.3% | -61.6% |
| Gross margin | 98.8% | – |
| Operating margin | -394.3% | -5,945.5% |
| Net margin | -369.3% | -5,477.2% |
| Return on equity | -224.9% | -19.8% |
| Analyst target vs. price | +307.2% | +171.5% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 33 | 45 |
| 30-day volatility | 104.3% | 62.6% |
| Max drawdown, 1 year | -50.0% | -46.3% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ATTO is the largest of the group by market value.
- KURA is growing revenue fastest.
- KURA keeps the most profit per dollar of sales.
- ATTO has been the calmest stock over the last 30 days.